These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35105965)

  • 1. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
    Friend BD; Muhsen IN; Patel S; Hill LC; Lulla P; Ramos CA; Pingali SR; Kamble RT; John TD; Salem B; Bhar S; Doherty EE; Craddock J; Sasa G; Wu M; Wang T; Martinez C; Krance RA; Heslop HE; Carrum G
    Bone Marrow Transplant; 2022 Apr; 57(4):579-585. PubMed ID: 35105965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
    [No Abstract]   [Full Text] [Related]  

  • 4. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Wu R; Ma L
    Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
    Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
    Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
    Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Results of Rituximab Pre- and Post-BEAM with or without
    Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
    Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
    [No Abstract]   [Full Text] [Related]  

  • 12. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
    Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
    Isidori A; Christofides A; Visani G
    Leuk Lymphoma; 2016 Nov; 57(11):2499-509. PubMed ID: 27243412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
    Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
    Holmberg LA; Maloney DG; Connelly-Smith L
    Acta Haematol; 2024; 147(3):300-309. PubMed ID: 37708877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
    Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
    Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients.
    Deveci B; Ateşoğlu EB; Bayrak E; Kublashvili G; Toptaş T; Saba R; Gülbaş Z
    Transplant Proc; 2023; 55(1):235-241. PubMed ID: 36639277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.